Acasti Pharma Inc. said it fell out of Nasdaq's bid price listing requirement.
The Canadian biopharmaceutical company, the bid price of which was below the exchange's $1 minimum requirement, has 180 calendar days, or until Dec. 3, to regain compliance.
The notice has no immediate effect on Acasti Pharma's listing.
